Targeting myocardial inflammation: investigating the therapeutic potential of atrial natriuretic peptide in atrial fibrosis.
ANP
Atrial fibroblasts
Atrial fibrosis
Inflammation
Tenascin-C
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
15 Apr 2024
15 Apr 2024
Historique:
received:
18
12
2023
accepted:
28
02
2024
medline:
16
4
2024
pubmed:
16
4
2024
entrez:
15
4
2024
Statut:
epublish
Résumé
Atrial Fibrillation (AF), a prevalent arrhythmic condition, is intricately associated with atrial fibrosis, a major pathological contributor. Central to the development of atrial fibrosis is myocardial inflammation. This study focuses on Atrial Natriuretic Peptide (ANP) and its role in mitigating atrial fibrosis, aiming to elucidate the specific mechanisms by which ANP exerts its effects, with an emphasis on fibroblast dynamics. The study involved forty Sprague-Dawley rats, divided into four groups: control, Angiotensin II (Ang II), Ang II + ANP, and ANP only. The administration of 1 µg/kg/min Ang II was given to Ang II and Ang II + ANP groups, while both Ang II + ANP and ANP groups received 0.1 µg/kg/min ANP intravenously for a duration of 14 days. Cardiac fibroblasts were used for in vitro validation of the proposed mechanisms. The study observed that rats in the Ang II and Ang II + ANP groups showed an increase in blood pressure and a decrease in body weight, more pronounced in the Ang II group. Diastolic dysfunction, a characteristic of the Ang II group, was alleviated by ANP. Additionally, ANP significantly reduced Ang II-induced atrial fibrosis, myofibroblast proliferation, collagen overexpression, macrophage infiltration, and the elevated expression of Interleukin 6 (IL-6) and Tenascin-C (TN-C). Transcriptomic sequencing indicated enhanced PI3K/Akt signaling in the Ang II group. Furthermore, in vitro studies showed that ANP, along with the PI3K inhibitor LY294002, effectively reduced PI3K/Akt pathway activation and the expression of TN-C, collagen-I, and collagen-III, which were induced by Ang II. The study demonstrates ANP's potential in inhibiting myocardial inflammation and reducing atrial fibrosis. Notably, ANP's effect in countering atrial fibrosis seems to be mediated through the suppression of the Ang II-induced PI3K/Akt-Tenascin-C signaling pathway. These insights enhance our understanding of AF pathogenesis and position ANP as a potential therapeutic agent for treating atrial fibrosis.
Sections du résumé
BACKGROUND
BACKGROUND
Atrial Fibrillation (AF), a prevalent arrhythmic condition, is intricately associated with atrial fibrosis, a major pathological contributor. Central to the development of atrial fibrosis is myocardial inflammation. This study focuses on Atrial Natriuretic Peptide (ANP) and its role in mitigating atrial fibrosis, aiming to elucidate the specific mechanisms by which ANP exerts its effects, with an emphasis on fibroblast dynamics.
METHODS AND RESULTS
RESULTS
The study involved forty Sprague-Dawley rats, divided into four groups: control, Angiotensin II (Ang II), Ang II + ANP, and ANP only. The administration of 1 µg/kg/min Ang II was given to Ang II and Ang II + ANP groups, while both Ang II + ANP and ANP groups received 0.1 µg/kg/min ANP intravenously for a duration of 14 days. Cardiac fibroblasts were used for in vitro validation of the proposed mechanisms. The study observed that rats in the Ang II and Ang II + ANP groups showed an increase in blood pressure and a decrease in body weight, more pronounced in the Ang II group. Diastolic dysfunction, a characteristic of the Ang II group, was alleviated by ANP. Additionally, ANP significantly reduced Ang II-induced atrial fibrosis, myofibroblast proliferation, collagen overexpression, macrophage infiltration, and the elevated expression of Interleukin 6 (IL-6) and Tenascin-C (TN-C). Transcriptomic sequencing indicated enhanced PI3K/Akt signaling in the Ang II group. Furthermore, in vitro studies showed that ANP, along with the PI3K inhibitor LY294002, effectively reduced PI3K/Akt pathway activation and the expression of TN-C, collagen-I, and collagen-III, which were induced by Ang II.
CONCLUSIONS
CONCLUSIONS
The study demonstrates ANP's potential in inhibiting myocardial inflammation and reducing atrial fibrosis. Notably, ANP's effect in countering atrial fibrosis seems to be mediated through the suppression of the Ang II-induced PI3K/Akt-Tenascin-C signaling pathway. These insights enhance our understanding of AF pathogenesis and position ANP as a potential therapeutic agent for treating atrial fibrosis.
Identifiants
pubmed: 38622341
doi: 10.1007/s11033-024-09393-w
pii: 10.1007/s11033-024-09393-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
506Informations de copyright
© 2024. The Author(s).
Références
Akkaya E, Berkowitsch A, Zaltsberg S et al (2018) Second-generation cryoballoon ablation as a first-line treatment of symptomatic atrial fibrillation: two-year outcome and predictors of recurrence after a single procedure. Int J Cardiol 259:76–81. https://doi.org/10.1016/j.ijcard.2017.11.011
doi: 10.1016/j.ijcard.2017.11.011
pubmed: 29579615
Bencivenga L, Komici K, Nocella P et al (2020) Atrial fibrillation in the elderly: a risk factor beyond stroke. Ageing Res Rev 61:101092. https://doi.org/10.1016/j.arr.2020.101092
doi: 10.1016/j.arr.2020.101092
pubmed: 32479927
Soares-Miranda L, Sattelmair J, Chaves P et al (2014) Physical activity and heart rate variability in older adults: the Cardiovascular Health Study.Circulation.129. 212100–2110. https://doi.org/10.1161/CIRCULATIONAHA.113.005361
Elliott AD, Middeldorp ME, Van Gelder IC et al (2023) Epidemiology and modifiable risk factors for atrial fibrillation. Nat Rev Cardiol 20(6):404–417. https://doi.org/10.1038/s41569-022-00820-8
doi: 10.1038/s41569-022-00820-8
pubmed: 36600003
Fiala M, Wichterle D, Bulková V et al (2014) A prospective evaluation of haemodynamics, functional status, and quality of life after radiofrequency catheter ablation of long-standing persistent atrial fibrillation. Europace 16(1):15–25. https://doi.org/10.1093/europace/eut161
doi: 10.1093/europace/eut161
pubmed: 23851514
Sepehri Shamloo A, Dagres N, Dinov B et al (2019) Is epicardial fat tissue associated with atrial fibrillation recurrence after ablation? A systematic review and meta-analysis. Int J Cardiol Heart Vasc 22:132–138. https://doi.org/10.1016/j.ijcha.2019.01.003
doi: 10.1016/j.ijcha.2019.01.003
pubmed: 30740509
pmcid: 6356021
Das M, Loveday JJ, Wynn GJ, Gomes S et al (2017) Ablation index, a novel marker of ablation lesion quality: prediction of pulmonary vein reconnection at repeat electrophysiology study and regional differences in target values. Europace 19(5):775–783. https://doi.org/10.1093/europace/euw105
doi: 10.1093/europace/euw105
pubmed: 27247002
Burstein B, Nattel S (2008) Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 51(8):802–809. https://doi.org/10.1016/j.jacc.2007.09.064
doi: 10.1016/j.jacc.2007.09.064
pubmed: 18294563
Siebermair J, Kholmovski EG, Marrouche N (2017) Assessment of Left Atrial Fibrosis by late gadolinium enhancement magnetic resonance imaging: methodology and clinical implications. JACC Clin Electrophysiol 3(8):791–802. https://doi.org/10.1016/j.jacep.2017.07.004
doi: 10.1016/j.jacep.2017.07.004
pubmed: 29759774
Kim N, Jung Y, Nam M et al (2017) Angiotensin II affects inflammation mechanisms via AMPK-related signalling pathways in HL-1 atrial myocytes. Sci Rep 7(1):10328. https://doi.org/10.1038/s41598-017-09675-3
doi: 10.1038/s41598-017-09675-3
pubmed: 28871102
pmcid: 5583339
Forrester SJ, Booz GW, Sigmund CD et al (2018) Angiotensin II Signal transduction: an update on mechanisms of physiology and pathophysiology. Physiol Rev 98(3):1627–1738. https://doi.org/10.1152/physrev.00038.2017
doi: 10.1152/physrev.00038.2017
pubmed: 29873596
pmcid: 6335102
Fiebeler A, Nussberger J, Shagdarsuren E et al (2005) Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 111(23):3087–3094. https://doi.org/10.1161/CIRCULATIONAHA.104.521625
doi: 10.1161/CIRCULATIONAHA.104.521625
pubmed: 15939810
Tajiri K, Yonebayashi S, Li S et al (2021) Immunomodulatory role of Tenascin-C in myocarditis and inflammatory cardiomyopathy. Front Immunol 12:624703. https://doi.org/10.3389/fimmu.2021.624703
doi: 10.3389/fimmu.2021.624703
pubmed: 33692798
pmcid: 7938317
Tsukada B, Terasaki F, Shimomura H et al (2009) High prevalence of chronic myocarditis in dilated cardiomyopathy referred for left ventriculoplasty: expression of tenascin C as a possible marker for inflammation. Hum Pathol 40(7):1015–1022. https://doi.org/10.1016/j.humpath.2008.12.017
doi: 10.1016/j.humpath.2008.12.017
pubmed: 19297005
Udalova IA, Ruhmann M, Thomson SJ et al (2011) Expression and immune function of tenascin-C. Crit Rev Immunol 31(2):115–145. https://doi.org/10.1615/critrevimmunol.v31.i2.30
doi: 10.1615/critrevimmunol.v31.i2.30
pubmed: 21542790
Triposkiadis F, Pieske B, Butler J et al (2016) Global left atrial failure in heart failure. Eur J Heart Fail 18(11):1307–1320. https://doi.org/10.1002/ejhf.645
doi: 10.1002/ejhf.645
pubmed: 27813305
Ichiki T, Burnett JC Jr (2017) Atrial natriuretic peptide—old but new Therapeutic in Cardiovascular diseases. Circ J 81(7):913–919. https://doi.org/10.1253/circj.CJ-17-0499
doi: 10.1253/circj.CJ-17-0499
pubmed: 28552863
Lyu T, Zhao Y, Zhang T et al (2014) Natriuretic peptides as an adjunctive treatment for acute myocardial infarction: insights from the meta-analysis of 1,389 patients from 20 trials. Int Heart J 55(1):8–16. https://doi.org/10.1536/ihj.13-109
doi: 10.1536/ihj.13-109
pubmed: 24463927
Fujita S, Shimojo N, Terasaki F et al (2013) Atrial natriuretic peptide exerts protective action against angiotensin II-induced cardiac remodeling by attenuating inflammation via endothelin-1/endothelin receptor A cascade. Heart Vessels 28(5):646–657. https://doi.org/10.1007/s00380-012-0311-0
doi: 10.1007/s00380-012-0311-0
pubmed: 23277455
Li T, Tong Q, Wang Z, Yang Z et al (2023) Epigallocatechin-3-Gallate inhibits Atrial Fibrosis and reduces the Occurrence and Maintenance of Atrial Fibrillation and its possible mechanisms. Cardiovasc Drugs Ther. https://doi.org/10.1007/s10557-023-07447-y
doi: 10.1007/s10557-023-07447-y
pubmed: 38108918
pmcid: 10959818
Khalil H, Kanisicak O, Prasad V et al (2017) Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis. J Clin Invest 127(10):3770–3783. https://doi.org/10.1172/JCI94753
doi: 10.1172/JCI94753
pubmed: 28891814
pmcid: 5617658
Reese-Petersen AL, Olesen MS, Karsdal MA et al (2020) Atrial fibrillation and cardiac fibrosis: a review on the potential of extracellular matrix proteins as biomarkers. Matrix Biol 91–92:188–203. https://doi.org/10.1016/j.matbio.2020.03.005
doi: 10.1016/j.matbio.2020.03.005
pubmed: 32205152
Nattel S (2017) Molecular and Cellular mechanisms of Atrial Fibrosis in Atrial Fibrillation. JACC Clin Electrophysiol 3(5):425–435. https://doi.org/10.1016/j.jacep.2017.03.002
doi: 10.1016/j.jacep.2017.03.002
pubmed: 29759598
Tanaka H, Sun T, Kinashi H et al (2022) Interleukin-6 blockade reduces salt-induced cardiac inflammation and fibrosis in subtotal nephrectomized mice. Am J Physiol Ren Physiol 323(6):F654–F665. https://doi.org/10.1152/ajprenal.00396.2021
doi: 10.1152/ajprenal.00396.2021
Zhang Z, Tang J, Song J et al (2022) Elabela alleviates ferroptosis, myocardial remodeling, fibrosis and heart dysfunction in hypertensive mice by modulating the IL-6/STAT3/GPX4 signaling. Free Radic Biol Med 181:130–142. https://doi.org/10.1016/j.freeradbiomed
doi: 10.1016/j.freeradbiomed
pubmed: 35122997
Ohkura SI, Usui S, Takashima SI et al (2017) Augmented sphingosine 1 phosphate receptor-1 signaling in cardiac fibroblasts induces cardiac hypertrophy and fibrosis through angiotensin II and interleukin-6. PLoS ONE 12(8):e0182329. https://doi.org/10.1371/journal.pone.0182329
doi: 10.1371/journal.pone.0182329
pubmed: 28771545
pmcid: 5542600
Mouton AJ, Li X, Hall ME et al (2020) Obesity, hypertension, and Cardiac Dysfunction: Novel roles of Immunometabolism in Macrophage activation and inflammation. Circ Res 126(6):789–806. https://doi.org/10.1161/CIRCRESAHA.119.312321
doi: 10.1161/CIRCRESAHA.119.312321
pubmed: 32163341
pmcid: 7255054
Lv SL, Zeng ZF, Gan WQ et al (2021) Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation. Acta Pharmacol Sin 42(12):2016–2032. https://doi.org/10.1038/s41401-021-00703-7
doi: 10.1038/s41401-021-00703-7
pubmed: 34226664
pmcid: 8632984
Yang B, Zhao Y, Luo W et al (2023) Macrophage DCLK1 promotes obesity-induced cardiomyopathy via activating RIP2/TAK1 signaling pathway. Cell Death Dis 14(7):419. https://doi.org/10.1038/s41419-023-05960-4
doi: 10.1038/s41419-023-05960-4
pubmed: 37443105
pmcid: 10345119
Matsui K, Torii S, Hara S et al (2023) Tenascin-C in tissue repair after myocardial infarction in humans. Int J Mol Sci 24(12):10184. https://doi.org/10.3390/ijms241210184
doi: 10.3390/ijms241210184
pubmed: 37373332
pmcid: 10299348
Imanaka-Yoshida K, Tawara I, Yoshida T (2020) Tenascin-C in cardiac disease: a sophisticated controller of inflammation, repair, and fibrosis. Am J Physiol Cell Physiol 319(5):C781–C796. https://doi.org/10.1152/ajpcell.00353.2020 . Epub 2020 Aug 26. PMID: 32845719
doi: 10.1152/ajpcell.00353.2020
pubmed: 32845719
Machino-Ohtsuka T, Tajiri K, Kimura T et al (2014) Tenascin-C aggravates autoimmune myocarditis via dendritic cell activation and Th17 cell differentiation. J Am Heart Assoc 3(6):e001052. https://doi.org/10.1161/JAHA.114.001052
doi: 10.1161/JAHA.114.001052
pubmed: 25376187
pmcid: 4338691
Shimojo N, Hashizume R, Kanayama K et al (2015) Tenascin-C may accelerate cardiac fibrosis by activating macrophages via the integrin αVβ3/nuclear factor-κB/interleukin-6 axis. Hypertension 66(4):757–766. https://doi.org/10.1161/HYPERTENSIONAHA.115.06004
doi: 10.1161/HYPERTENSIONAHA.115.06004
pubmed: 26238448
Kimura T, Tajiri K, Sato A et al (2019) Tenascin-C accelerates adverse ventricular remodelling after myocardial infarction by modulating macrophage polarization. Cardiovasc Res. 115(3):614–624. https://doi.org/10.1093/cvr/cvy244 . PMID: 30295707
El-Karef A, Yoshida T, Gabazza EC et al (2007) Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis in mice. J Pathol. 211(1):86–94. https://doi.org/10.1002/path.2099 . PMID: 17121418
Mehta BB, Tiwari A, Sharma S et al (2018) Amelioration of collagen antibody induced arthritis in mice by an antibody directed against the fibronectin type III repeats of tenascin-C: targeting fibronectin type III repeats of tenascin-C in rheumatoid arthritis. Int Immunopharmacol 58:15–23. https://doi.org/10.1016/j.intimp.2018.02.022
doi: 10.1016/j.intimp.2018.02.022
pubmed: 29529488
Najenson AC, Courreges AP, Perazzo JC et al (2018) Atrial natriuretic peptide reduces inflammation and enhances apoptosis in rat acute pancreatitis. Acta Physiol (Oxf) 222(3). https://doi.org/10.1111/apha.12992
Chen C, Zhang Y, Tao M et al (2022) Atrial natriuretic peptide attenuates colitis via inhibition of the cGAS-STING pathway in Colonic epithelial cells. Int J Biol Sci 18(4):1737–1754. https://doi.org/10.7150/ijbs.67356
doi: 10.7150/ijbs.67356
pubmed: 35280696
pmcid: 8898360
Sánchez-Aguilar M, Ibarra-Lara L, Cano-Martínez A et al (2023) PPAR alpha activation by Clofibrate Alleviates Ischemia/Reperfusion Injury in metabolic syndrome rats by decreasing cardiac inflammation and remodeling and by regulating the Atrial Natriuretic Peptide Compensatory Response. Int J Mol Sci 24(6):5321. https://doi.org/10.3390/ijms24065321
doi: 10.3390/ijms24065321
pubmed: 36982395
pmcid: 10049157
Shiomi Y, Yokokawa M, Uzui H et al (2020) Serum tenascin-C levels in atrium predict atrial structural remodeling processes in patients with atrial fibrillation. J Interv Card Electrophysiol 59(2):401–406. https://doi.org/10.1007/s10840-019-00670-4
doi: 10.1007/s10840-019-00670-4
pubmed: 31820271
Xiang M, Liu T, Tian C et al (2022) Kinsenoside attenuates liver fibro-inflammation by suppressing dendritic cells via the PI3K-AKT-FoxO1 pathway. Pharmacol Res 177:106092. https://doi.org/10.1016/j.phrs.2022.106092
doi: 10.1016/j.phrs.2022.106092
pubmed: 35066108
pmcid: 8776354
Zhang XL, Li B, Zhang X et al (2022) 18β-Glycyrrhetinic acid monoglucuronide (GAMG) alleviates single-walled carbon nanotubes (SWCNT)-induced lung inflammation and fibrosis in mice through PI3K/AKT/NF-κB signaling pathway. Ecotoxicol Environ Saf 242:113858. https://doi.org/10.1016/j.ecoenv.2022.113858
doi: 10.1016/j.ecoenv.2022.113858
pubmed: 35809393
Wang Z, Chen Z, Li B et al (2020) Curcumin attenuates renal interstitial fibrosis of obstructive nephropathy by suppressing epithelial-mesenchymal transition through inhibition of the TLR4/NF-кB and PI3K/AKT signalling pathways. Pharm Biol 58(1):828–837. https://doi.org/10.1080/13880209.2020.1809462
doi: 10.1080/13880209.2020.1809462
pubmed: 32866059
pmcid: 7470153